Citius Pharmaceuticals, Inc. Receives "Fast Track" Designation By FDA For Mino-Lok™ Investigational Trial Oct 31, 2017
Citius Pharmaceuticals to Present at the Dawson James 2017 Small Cap Growth Stock Conference Oct 17, 2017
Citius Pharmaceuticals, Inc. Provides Phase 3 Update On Mino-Lok™ Clinical Trial Following FDA Meeting Sep 5, 2017
Citius Pharmaceuticals, Inc. Prices $6,800,000 Public Offering And Listing On The Nasdaq Capital Market Aug 3, 2017
Citius Pharmaceuticals Announces US Patent Office Publication Of Enhanced Stability Patent Application Covering Mino-Lok™ Jun 20, 2017
